

## Special Issue

# Integrating Tumor Evolution Dynamics into the Treatment of Cancer

### Message from the Guest Editor

We are pleased to invite you to submit your research to this Special Issue which invites studies integrating tumor evolution dynamics into the treatment of cancer. Despite recent approvals of targeted therapies and immunotherapies, stage IV cancer remains incurable. While continued development of new drugs is needed, we believe that improved survival of metastatic cancer can be obtained through better utilization of existing agents using treatment strategies guided by intra-tumor evolutionary dynamics. Over the past 10 years, oncologists, evolutionary biologists, mathematicians, and cancer biologists have teamed up to challenge the current threat to a progression paradigm. The promises of the adaptive therapy approach have been seen in early-phase prostate cancer trials. I would like to invite you to submit your original research papers, reviews, communications, and clinical trial papers. Our goal is to facilitate communications and collaborations in this emerging field. Clinical trials with meaningful but negative results, or ongoing clinical trials with a novel design, will be accepted as well.

### Guest Editor

Dr. Jingsong Zhang  
Moffitt Cancer Center, Tampa, FL, USA

### Deadline for manuscript submissions

closed (31 January 2024)



## Cancers

---

an Open Access Journal  
by MDPI

---

**Impact Factor 4.4**  
**CiteScore 8.8**  
**Indexed in PubMed**



[mdpi.com/si/118385](https://mdpi.com/si/118385)

*Cancers*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[cancers@mdpi.com](mailto:cancers@mdpi.com)

[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)





# Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)



## About the Journal

### Message from the Editor-in-Chief

*Cancers* is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

---

### Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)